Pau Montesinos, MD discusses key updates from the global phase 3 AGILE study, as presented at the 2022 American Society of Hematology Annual Meeting, and speaks to the clinical implications of these data.
Which JAK Inhibitor in Myelofibrosis: Deciding Factors in Treatment Selection
Revisit the OncLive On Air Episodes From February 2024
SLS009 Plus Venetoclax/Azacitidine Produces Responses in R/R AML, Including ASXL1+ Disease
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy
State of the Science Summit - Hematologic Malignancies: Chaired by Catherine E. Lai, MD, MPH
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma